DRG Instruments
DRG Instruments GmbH is a German in vitro diagnostics manufacturer, founded 1973 and based in Marburg, that develops ELISA and chemiluminescence immunoassays and the DRG:HYBRiD-XL automated analyzer, serving clinical laboratories, hospitals, and veterinary diagnostics customers across more than 110 countries as a subsidiary of DRG International Inc.
- Company typePrivate
- Founded1970
- HeadquartersMarburg, Germany
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What DRG Instruments does
DRG Instruments GmbH, headquartered in Marburg, Germany, is a privately held in vitro diagnostics (IVD) manufacturer specializing in immunoassay technologies, principally Enzyme-Linked Immunosorbent Assays (ELISA) and Chemiluminescence Immunoassays (CLIA). Founded in 1973 as the German subsidiary of DRG International Inc. (established 1970 in New Jersey), the company develops, produces, and distributes diagnostic kits and analyzers across endocrinology, diabetes, infectious diseases, tumor markers, cardiovascular disease, thyroid function, prenatal/neonatal care, fertility, and veterinary diagnostics. Its proprietary DRG:HYBRiD-XL platform is a benchtop, random-access analyzer that simultaneously runs immunoassays and clinical chemistry from a single patient sample, supported by accessories such as the Fecal Extraction System. The company holds several first-in-class innovations, including the world's first nonradioactive immunoassays for active Renin and PLGF, the world's first Hepcidin ELISA (2003), and the world's first CMV IgG ELISA using buccal swab samples (2018), and is certified to ISO 13485:2016 by TÜV Rheinland.
The business operates a B2B distribution model through wholly-owned subsidiaries in Germany, Russia, Poland, and the Czech Republic, complemented by a network of local distributors covering more than 110 countries. Pricing is quote-based with no public list prices; sales rely heavily on trade show presence at MEDICA (Düsseldorf), MEDLAB Middle East, ADLM (formerly AACC), and Euromedlab. Revenue streams flow from one-time sales of diagnostic kits (96-well or 40-test formats), laboratory equipment (HYBRiD-XL analyzers, plate readers/washers), consumables/disposables, and a veterinary diagnostics line. In 2024–2025 the company expanded its automated menu (improved fecal Calprotectin), launched a new DRG Neuroscience business unit featuring a Traumatic Brain Injury (TBI) test panel (GFAP and UCH-L1) on the BioCheck DxDATA CLIA platform, transitioned to electronic Instructions for Use (eIFU), and renewed its long-standing German distribution partnership with Mercodia.
Strategically, DRG combines internal R&D and proprietary assay development in Marburg with partnerships to extend reach — notably the joint-exhibition relationship with BioCheck for automated CLIA platforms and the renewed Mercodia alliance for cardiometabolic biomarkers. The product-market positioning targets clinical laboratories and hospitals as the primary segment, with secondary segments in research institutions and veterinary diagnostics. The company is led by Managing Director Michael Schröder, with Dr. Matthias Herkert heading R&D and Dr. Hero Brahms leading quality management and production, and reports a headcount in the 11–50 range.
DRG Instruments firmographics
Firmographics- Name
- DRG Instruments
- Legal name
- DRG Instruments GmbH
- Website
- https://drg-diagnostics.de
- Company type
- Private
- Founded year
- 1970
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- DRG Instruments GmbH is a German in vitro diagnostics manufacturer, founded 1973 and based in Marburg, that develops ELISA and chemiluminescence immunoassays and the DRG:HYBRiD-XL automated analyzer, serving clinical laboratories, hospitals, and veterinary diagnostics customers across more than 110 countries as a subsidiary of DRG International Inc.
- Ownership category
- akta.pro rank
Where DRG Instruments is headquartered
LocationHeadquarters
- HQ city
- Marburg
- HQ country
- Germany
- HQ region
- Europe
Offices6 records
Markets served
DRG Instruments business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Diagnostic Reagents and Kits: Sale of ELISA and CLIA assay kits for various diagnostic parameters including endocrinology, diabetes, infectious diseases, tumor markers, and more. Products sold as 96-well or 40-test kit formats.
- Laboratory Equipment: Sale and distribution of the DRG:HYBRiD-XL fully automated analyzer and related equipment including MTPL readers, washers, and shakers.
- Laboratory Consumables and Disposables: Supply of laboratory consumables including pipette tips, tubes, extraction supplies, and controls for ELISA testing procedures.
- Veterinary Diagnostics: Specialized ELISAs and rapid tests for veterinary applications including canine, feline, bovine, equine, porcine, and avian diagnostics.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | B2B diagnostic products - quote-based pricing |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels4 records
DRG Instruments product offering
Product offeringCore offering
DRG Instruments GmbH manufactures and distributes in vitro diagnostic immunoassay kits (ELISA and Chemiluminescence/CLIA) plus the DRG:HYBRiD-XL fully automated random-access analyzer that combines immunoassays and clinical chemistry on a single benchtop platform. Its product menu covers endocrinology, infectious diseases, tumor markers, diabetes, cardiovascular, thyroid, prenatal/neonatal, salivary diagnostics and veterinary applications, supported by laboratory disposables, controls, sample-prep devices and an electronic Instructions for Use (eIFU) portal.
Product overview
DRG Instruments GmbH is a multinational medical diagnostics manufacturer specializing in immunoassay-based in vitro diagnostic products. The company operates a platform-plus-products model centered on two main assay technologies: manual ELISA kits and the fully automated DRG:HYBRiD-XL analyzer. The core product portfolio includes specialized assays across diagnostic categories including endocrinology (hormones, thyroid function), infectious diseases, tumor markers, diabetes diagnostics, autoimmune diseases, and veterinary diagnostics. The DRG:HYBRiD-XL serves as the automated platform for running a subset of DRG's assay menu, while manual ELISAs cover the broader product range. Supporting offerings include sample preparation equipment (Fecal Extraction System, SPEC Disk Technology), laboratory disposables, quality controls, and the eIFU electronic documentation portal. The company also features BioCheck's DxDATA chemiluminescence system for specific automated testing needs. Distribution spans over 110 countries through subsidiaries and local distributors.
Differentiator
Problem solved
Functional benefit
Brands
- DRG:HYBRiD-XL®: Fully automated random access analyzer for immunoassays and clinical chemistry parameters
- DRG Neuroscience
- CMV IgG Buccal Swab ELISA
Products and services
- DRG:HYBRiD-XL Analyzer Fully automated random-access benchtop analyzer (60.8 x 63.5 x 58.6 cm) that simultaneously performs immunoassays and clinical chemistry (including turbidimetric) parameters from one patient sample, with up to 40 samples per run, barcoded sample/reagent reading, and support for serum, plasma, stool, urine or saliva samples. For clinical laboratories and hospitals performing routine and specialized immunoassay testing.
- DRG ELISA Kits Manual Enzyme-Linked Immunosorbent Assay kits for biomarker detection across endocrinology, infectious diseases, tumor markers, thyroid function, fertility/pregnancy, cardiovascular, vitamins, growth factors, neuropeptides, bone and mineral metabolism, leukotrienes and prostaglandins, autoimmune diseases, drug monitoring, and pituitary/adrenal function. Sold as 96-well or 40-test kit formats. For clinical diagnostic laboratories and hospitals.
- CMV IgG Buccal Swab ELISA Quantitative and qualitative detection of IgG antibodies against Cytomegalovirus (CMV) from human buccal swab samples. Non-invasive alternative to blood plasma CMV monitoring for transplantation donor screening or population studies. Validated with 99.1% sensitivity and 98.6% specificity. For donor screening organizations, transplant programs, and research use.
- DxDATA Automated CLIA Analyzer (with DRG Neuroscience TBI Test Panel) Automated chemiluminescent immunoassay (CLIA) analyzer platform from BioCheck featured alongside DRG's product offerings; fully automated CLIA TBI test panel (GFAP and UCH-L1) measures brain injury biomarkers within 30 minutes from serum. For clinical laboratories, emergency medicine, and trauma centers.
- DRG Hepcidin ELISA Quantitative measurement of hepcidin in serum/plasma for assessment of iron metabolism and iron-related disorders such as anemia of chronic disease and iron overload conditions. Available in manual ELISA and automated DRG:HYBRiD-XL formats. For clinical laboratories and research institutions.
- DRG Saliva ELISA Kits Non-invasive salivary assay kits for quantitative determination of steroid hormones including Cortisol, DHEA, Testosterone, Estradiol, Progesterone, and 17-OH Progesterone. FDA approval received for 17-OH Progesterone Saliva Kit in 2008. For endocrinology labs, sports medicine, fertility clinics, and research institutions.
- DRG Infectious Diseases ELISA Kits Comprehensive portfolio of ELISAs for infectious disease detection covering viral, bacterial, parasitic and fungal pathogens, including TORCH panel, respiratory infections, vector-borne diseases, Avian Influenza A, CMV, and Fasciola. Over 70 infectious disease ELISAs brought in through the 2003 Novum-Diagnostics acquisition. For clinical and veterinary laboratories.
- DRG 25-OH Vitamin D Total ELISA Quantitative determination of total 25-hydroxyvitamin D in serum or plasma for assessment of vitamin D status. Available in both manual format and automated DRG:HYBRiD-XL format. For clinical laboratories.
- DRG Aldosterone ELISA Quantitative assay for aldosterone determination in serum/plasma for research and clinical applications including assessment of the renin-angiotensin-aldosterone system (RAAS). Available in manual and automated DRG:HYBRiD-XL formats. For endocrinology laboratories and hypertension clinics.
- DRG Renin (active) ELISA World's first non-radioactive immunoassay for the determination of active Renin in human plasma for the workup of hypertension and disorders of the renin-angiotensin system. Available in manual and automated DRG:HYBRiD-XL formats. For endocrinology and hypertension laboratories.
- DRG Veterinary Diagnostics ELISA Kits and Rapid Tests Specialized ELISAs and rapid tests for veterinary applications covering canine, feline, bovine, equine, porcine, and avian diagnostics, including infectious disease detection and hormone monitoring. For veterinary laboratories and animal health service providers.
- Rapid Screen Tests (DRG Occult-Detect, Entamoeba Ag, Leishmania Detect) Rapid point-of-care diagnostic tests including DRG Occult-Detect for fecal occult blood (CE marked), Entamoeba Ag test, and Leishmania Detect. For clinical laboratories and point-of-care settings.
- Growth Factors ELISA Kits ELISA kits for quantitative measurement of growth factors including IGF-1, IGF BP3, TGF-β1, Myostatin, and VEGF variants (sVEGF-Receptor 1, VEGF-A, VEGF-C). For research institutions, academic laboratories, and clinical studies.
- DRG Fecal Extraction System (FES) Device for hygienic stool sample extraction (catalog HYI-5989, 100 extraction tubes per box) that simplifies laborious stool preparation and integrates with the DRG:HYBRiD-XL analyzer for fully automated Calprotectin testing. For clinical laboratories performing gastrointestinal diagnostics.
- Laboratory Disposables Laboratory consumables including DRG Labpette pipettes, Eppendorf Multipette, Ritips, sample tubes, pipette tips, and stool sample preparation materials. For laboratories running ELISA and DRG:HYBRiD-XL workflows.
- Quality Controls Quality control sera and controls including Canine Control, Estrone-3-Sulfate Control, Rat Control, and Tumor Marker Control Sera for assay validation and routine QC of ELISA testing procedures. For clinical and veterinary laboratories.
- SPEC Disk Technology (Solid Phase Extraction Supplies) Solid phase extraction products using glass fiber matrix disk technology for reproducible sample preparation, available in multiple chemistries including C2, C8, C18, SCX, SAX, CN, NH2, SI, PH, MP1, and PSA variants. For analytical and clinical laboratories performing sample preparation.
Companies that use DRG Instruments
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
DRG Instruments technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
Feature4 records
DRG Instruments partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core, major and minor.
- MercodiacoreDRG renewed distribution partnership with Mercodia for the German market effective March 6, 2024. Mercodia is a Swedish biotech company with over 30 years of experience as a leading developer and manufacturer of immunoassays. The partnership, spanning over 20 years, focuses on distribution of biomarker assays in ELISA format, particularly for diabetes and cardiometabolic diseases including Insulin, C-Peptide, Proinsulin, Glucagon, GLP-1, GIP, Lp(a), oxidized LDL, and MPO.
- DKMS Life Science Lab gGmbHcoreValidation partnership for CMV IgG Buccal Swab ELISA. DKMS Life Science Lab conducted large-scale validation study demonstrating 99.1% sensitivity and 98.6% specificity on dried buccal swab samples for CMV serostatus determination. Study validated the assay for use in stem cell donor registry context, analyzing over 80% of samples successfully. Published in Journal of Infectious Diseases (2021) and Transplantation Immunology (2022).
- BioCheckmajorJoint exhibition partnership at trade shows including ADLM/AACC 2023 and 2024. BioCheck manufactures the DxDATA automated chemiluminescent immunoassay system. Companies share exhibition booths and collaborate on product demonstrations, with DRG presenting its full immunoassay portfolio alongside BioCheck's CLIA platform.
- Diagnostics-4-Future ConferenceminorDRG is an official partner of the Diagnostics-4-Future Conference held annually in Konstanz, Germany. The conference brings together companies, laboratories, clinics, and research institutions for new diagnostic solutions. DRG participates as exhibitor and sponsor, with Dr. Matthias Herkert presenting on antibiotic resistance topics.
Scale indicators4 records
Recent moves7 records
Expansion highlights6 records
DRG Instruments competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key highlights8 records
Customer concentration
DRG Instruments social profiles
Digital presenceDRG Instruments compliance and trust
Trust signalCompliance5 records
DRG Instruments financial estimates
Financial estimateRevenue estimate
Valuation estimate
DRG Instruments leadership team
Management profileNumber of profiles
Profiles11 records
DRG Instruments subsidiaries and ownership
Company hierarchySubsidiaries5 records
DRG Instruments funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
DRG Instruments M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about DRG Instruments
What does DRG Instruments do?
DRG Instruments GmbH manufactures and distributes in vitro diagnostic immunoassay kits (ELISA and Chemiluminescence/CLIA) plus the DRG:HYBRiD-XL fully automated random-access analyzer that combines immunoassays and clinical chemistry on a single benchtop platform. Its product menu covers endocrinology, infectious diseases, tumor markers, diabetes, cardiovascular, thyroid, prenatal/neonatal, salivary diagnostics and veterinary applications, supported by laboratory disposables, controls, sample-prep devices and an electronic Instructions for Use (eIFU) portal.
Is DRG Instruments a public or private company?
DRG Instruments is a private company. It is classified as corporate owned and is currently operating.
When was DRG Instruments founded?
DRG Instruments was founded in 1970. It employs 11 to 50 people.
Where is DRG Instruments based?
DRG Instruments is headquartered in Marburg, Germany, in the Europe region.
How does DRG Instruments make money?
Four revenue lines are on record. Diagnostic Reagents and Kits are the primary driver. The others are laboratory Equipment, laboratory Consumables and Disposables and veterinary Diagnostics.
Does DRG Instruments have an API?
No public API is recorded for DRG Instruments.